Galapagos Rises Most in Three Years in Brussels on Abbott Deal

Galapagos NV (GLPG) rose the most in more than three years in Brussels trading after agreeing to license an experimental drug to Abbott Laboratories. (ABT)

Galapagos climbed 26 percent to 13.69 euros at 9:20 a.m. The stock’s intraday gain was the biggest since Feb. 13, 2009.

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.